MYOV Myovant Science

Myovant Sciences Appoints Lauren Merendino as Chief Commercial Officer

Myovant Sciences Appoints Lauren Merendino as Chief Commercial Officer

BASEL, Switzerland, April 05, 2021 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced the appointment of Lauren Merendino as Chief Commercial Officer of Myovant Sciences, Inc., effective April 5, 2021. Ms. Merendino brings over 20 years of pharmaceutical and biotech leadership experience to Myovant, with expertise in building and leading commercial teams accompanied by a record of successful product launches. She most recently served as Vice President, Neurological Rare Diseases at Genentech. Ms. Merendino will be a member of Myovant’s Executive Committee, reporting directly to Chief Executive Officer David Marek.

“We are thrilled to welcome Lauren, who joins Myovant at a pivotal point following our transition into a commercial-stage company,” said Mr. Marek. “The recent FDA approval in advanced prostate cancer and our upcoming regulatory milestones in uterine fibroids and endometriosis set us up for an exciting path forward. Lauren’s experience of building and leading top-performing commercial teams will be critical in enabling our therapies to reach patients who can benefit the most. I also want to sincerely thank Adele Gulfo for serving as the interim Chief Commercial Officer over the past year and for her continued support as a member of Myovant’s Board of Directors.”

Ms. Merendino is a seasoned commercial leader with experience across multiple therapeutic areas, including oncology and rare diseases, and across all stages of the product lifecycle. She has played a leadership role in multiple launches, with particular experience in oral therapies and buy-and-bill processes. In her most recent role as Vice President, Neurological Rare Diseases at Genentech, she led the cross-functional team including marketing, sales, market access, medical affairs, and government affairs, overseeing two brands, including the launch of a new treatment for spinal muscular atrophy. Over her tenure at Roche and Genentech, she held a variety of leadership positions spanning national sales, marketing, as well as commercial strategies for molecules in early development and business development deals.

“I am delighted to join Myovant and its highly talented team at this exciting moment in the company’s growth,” said Ms. Merendino. “I believe Myovant has a real opportunity to improve the lives of many women and men, not only with the medicines it is developing but also with its broader commitment to empowering women and men to be active participants in their care journeys.”

About Myovant Sciences 

Myovant Sciences aspires to redefine care for women and for men through purpose-driven science, empowering medicines, and transformative advocacy. We have one FDA-approved medicine, ORGOVYX™ (relugolix), for adult patients with advanced prostate cancer. Our lead product candidate, relugolix combination tablet (relugolix 40 mg, estradiol 1.0 mg, and norethindrone acetate 0.5 mg), is under regulatory review in Europe and the U.S. for women with uterine fibroids and is under development for women with endometriosis. We are also developing MVT-602, an oligopeptide kisspeptin-1 receptor agonist, which has completed a Phase 2a study for female infertility as part of assisted reproduction. Sumitovant Biopharma, Ltd., a wholly owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd., is our majority shareholder. For more information, please visit our website at . Follow  on Twitter and .

Investor Contact:

Ryan Crowe

Vice President, Investor Relations

Myovant Sciences, Inc.

+1 (650) 781-9106

Media Contact:

Albert Liao 

Director, Corporate Communications

Myovant Sciences, Inc.

+1 (650) 410-3055

A photo accompanying this announcement is available at

 



EN
05/04/2021

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Myovant Science

 PRESS RELEASE

Myovant Sciences Announces Corporate Updates and Financial Results for...

Myovant Sciences Announces Corporate Updates and Financial Results for Third Fiscal Quarter 2022 Third fiscal quarter 2022 total revenue of $100.2 million; including net product revenue of $61.4 millionNet product revenue from U.S. sales of ORGOVYX® of $48.7 million in third fiscal quarter 2022, with sequential quarterly demand volume growth of 13% and cumulative patients estimated at 26,000 through December 2022Net product revenue from U.S. sales of MYFEMBREE® of $10.5 million in third fiscal quarter 2022, with sequential quarterly demand volume growth of 49% and cumulative patients estima...

 PRESS RELEASE

Myovant Sciences Announces New Employment Inducement Grants Under NYSE...

Myovant Sciences Announces New Employment Inducement Grants Under NYSE Rule 303A.08 BASEL, Switzerland, Nov. 16, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a biopharmaceutical company that aspires to redefine care for women and for men through purpose-driven science, empowering medicines, and transformative advocacy, today announced that it approved equity awards for 18 new employees with a grant date of November 15, 2022 pursuant to Myovant’s 2020 Inducement Plan. The equity awards were granted to the employees joining Myovant in accordance with NYSE’s Listed Company Manual ...

 PRESS RELEASE

Myovant Sciences Appoints Ann Tomlin as Senior Vice President of Human...

Myovant Sciences Appoints Ann Tomlin as Senior Vice President of Human Resources BASEL, Switzerland, Nov. 16, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV) today announced the appointment of Ann Tomlin as Senior Vice President of Human Resources. Beginning November 28, Ms. Tomlin will be responsible for developing talent solutions and human resources strategies across Myovant’s global functions. She will serve as a member of the Executive Committee and will report to David Marek, Myovant’s Chief Executive Officer. Ms. Tomlin has over 25 years of human resources experience with a...

 PRESS RELEASE

Myovant Sciences Announces Corporate Updates and Financial Results for...

Myovant Sciences Announces Corporate Updates and Financial Results for Second Fiscal Quarter 2022 On October 23, 2022, Sumitovant Biopharma Ltd. (Sumitovant), in conjunction with parent company Sumitomo Pharma Co., Ltd. (Sumitomo Pharma), and Myovant Sciences (Myovant) announced that they have entered into a definitive agreement pursuant to which Sumitovant will acquire all outstanding shares of Myovant not already owned by Sumitovant for $27.00 per share in cash. This corresponds to a total transaction value of $1.7 billion on a fully diluted basis, and a total company value of $2.9 billio...

 PRESS RELEASE

Myovant Sciences Cancels Second Quarter Earnings Conference Call

Myovant Sciences Cancels Second Quarter Earnings Conference Call BASEL, Switzerland, Oct. 24, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV) (“Myovant”) today announced the cancellation of its earnings conference call for the quarter ended September 30, 2022 that had originally been scheduled for October 26, 2022 at 5:00 p.m. Eastern Time. The call is being cancelled due to the announcement of the pending merger with Sumitovant Biopharma Ltd. ABOUT MYOVANT SCIENCES Myovant Sciences aspires to redefine care for women and men through purpose-driven science, empowering medicines, a...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch